There have been reports of increased liver toxicity in people with HIV/AIDS on zidovudine or efavirenz when treated with<unk> -containing ACT regimens, therefore it is recommended that these people avoid<unk> . Pharmacokinetics and pharmacogenetics == It is bioactivated hepatically to its primary metabolite, N-desethylamodiaquine, by the cytochrome p450 enzyme CYP2C8. Among<unk>  users, several rare but serious side effects have been reported and linked to variants in the CYP2C8 alleles. CYP2C8*1 is characterized as the wild-type allele, which shows an acceptable safety profile, while CYP2C8*2, *3 and *4 all show a range of "poor metabolizer" phenotypes. People who are poor metabolizers of<unk>  display lower treatment efficacy against malaria, as well as increased toxicity. Several studies have been conducted to determine the prevalence of CYP2C8 alleles amongst malaria patients in East Africa, and have tentatively shown the variant alleles have significant prevalence in that population. About 3.6% of the population studied showed high risk for a poor reaction to or reduced treatment outcomes when treated with<unk> . This information is useful in developing programs of pharmacovigilance in East Africa, and have important clinical considerations for prescribing antimalarial medications in regions with high CYP2C8 variant frequency.
Amodiaquine
Primaquine
Tafenoquine
Piperaquine
Artemether
Chloroquine
Mefloquine
Delamanid